SCHEMBL7788151

SCHEMBL7788151

Nc1[nH]ncc1C(=O)N1CCc2cc(C(=O)NO)sc2C1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 10/20 0.55
TSHR P16473 1/20 0.35
ALDH1A1 P00352 3/20 0.35
MEN1 O00255 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
GAA P10253 1/20 0.35
CYP2C19 P33261 1/20 0.35
KMT2A Q03164 1/20 0.35
PRMT5 O14744 4/20 0.35
WDR77 Q9BQA1 4/20 0.35
KDM1A O60341 4/20 0.35
TP53 P04637 2/20 0.34
HPGD P15428 1/20 0.34
MAPK1 P28482 1/20 0.34
POLB P06746 1/20 0.34
HSP90AA1 P07900 1/20 0.34
SPR P35270 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7800057 0.77 HDAC6 (0.55) HDAC6ALDH1A1MEN1CYP1A2CYP3A4
SCHEMBL1174337 0.74 HDAC6 (0.60) HDAC6TSHRALDH1A1MEN1KMT2A
SCHEMBL1174355 0.73 HDAC6 (0.53) HDAC6ALDH1A1MEN1CYP1A2CYP3A4
SCHEMBL1174038 0.73 HDAC6 (0.61) HDAC6ALDH1A1PRMT5WDR77KDM1A
SCHEMBL1174100 0.73 HDAC6 (0.58) HDAC6ALDH1A1GAAPRMT5WDR77
SCHEMBL1173987 0.72 HDAC6 (0.56) HDAC6ALDH1A1PRMT5WDR77TP53
SCHEMBL1174425 0.72 HDAC6 (0.56) HDAC6TSHRALDH1A1HPGDMAPK1
SCHEMBL1173965 0.72 HDAC6 (0.61) HDAC6ALDH1A1PRMT5WDR77KDM1A
SCHEMBL1173768 0.72 HDAC6 (0.60) HDAC6ALDH1A1MEN1CYP1A2CYP3A4
SCHEMBL1173937 0.72 HDAC6 (0.80) HDAC6KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140329836-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-11-06 US disclosed
US-20140329836-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-11-06 US disclosed
US-20110046157-A1 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-02-24 US disclosed
US-20110046157-A1 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-02-24 US disclosed
WO-2010151317-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140329836-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC5, HDAC1 HDAC6 1/4885TSHR 3495/4885ALDH1A1 1220/4885
US-20110046157-A1 Substituted hydroxamic acids and uses thereof HDAC6, HDAC5, HDAC1 HDAC6 1/4885TSHR 3495/4885ALDH1A1 1220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.